Scott Rocklage has a Ph.D and over three decades of healthcare management experience. He got his education started at the University of California. There Scott received his Bachelor of Science in Chemistry. He continued on to receive his Ph.D in Chemistry at the Massachusetts Institute of Technology (MIT).
He is a board member for WaveRx, and VBI Vaccines. Scott is sits on the Board of Directors for Novira Therapeutics, Epirus Biopharmaceuticals, Rennovia, and Pulmatrix. On top of that he is a Board Chairman for Relypsa and a Board of Associates for Whitehead Institute for Biomedical Research. How does it do it all?
This does not including his main career or entrepreneurship. Scott Rocklage is currently a Managing Partner at 5AM Ventures. He joined the team as a Venture Partner in 2003, but after a year he became a Managing Partner. With his leadership efforts Scott helped three new U.S. New Drug Applications get approved by the FDA. Learn more about Scott Rocklage: http://www.thestylemaponline.com/the-amazing-career-of-scott-rocklage-of-5am-ventures/ and http://www.rennovia.com/team/scott-m-rocklage/
They are called Cubicin®, Teslascan®, and Omniscan™. His ideas are brought to life by working with other business-executives, physicians, scientists that are all entrepreneurs looking to treat unmet medical needs with medicine.
There is no typical day for this Ph.D because every day is different. One day he might be working with life science and others include working on 5AM portfolio. There are a few things that keep him productive as an entrepreneur. It’s all about being well organized.
Scott does with with schedules, calendars, time management, you name it. He suggests that to grow you have to take risks every once in a while. You won’t get rich working for someone else, you have to break away and try being an entrepreneur. It’s all important to stay true to your business model and don’t stray too far from it.
Work with your strengths even if it does not seem trendy at the time. If there was one book he could suggest to readers is “Good to Great.” It is a great book on understanding performance and business.
On that note, one trend that excites Scott is targeting genotypes and mutations to treat cancer. There is more to come from this Ph.D in the world of science.
Read more: Scott Rocklage | LinkedIn